Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Panitumumab|DRUG: Carboplatin|DRUG: Gemcitabine
Sponsor: SCRI Development Innovations, LLC
Collaborators: Amgen|Eli Lilly and Company